https://disruptivepharma.se/press-nyheter/ 2026-08-20T06:30:00+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-slutfor-omvant-forvarv-av-disruptive-pharma-och-genomfor-apportemission/ 2026-08-11T22:02:40+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:40+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-villkorat-godkannande-for-fortsatt-notering-pa-nasdaq-first-north-growth-market-och-offentliggor-bolagsbeskrivning/ 2026-08-11T22:02:40+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-informationsdokument-infor-extra-bolagsstamma/ 2026-08-11T22:02:40+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-initierar-transaktionsprocess-avseende-gtx-plattformen/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-har-ingatt-villkorat-avtal-om-omvant-forvarv-av-disruptive-pharma/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-28-maj-2026/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2026/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2025/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-informerar-om-observationsstatus-pa-nasdaq-first-north-growth-market/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-lamnar-uppdatering-avseende-strategisk-oversyn/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-for-2025/ 2026-08-11T22:02:41+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-idag-forandringar-i-bolagets-ledningsgrupp/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-ger-statusuppdatering-avseende-pagaende-strategisk-oversyn/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-blir-partner-i-europeiskt-forskningskonsortium-for-alports-syndrom/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2026/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-redeye-till-finansiell-radgivare-i-den-strategiska-oversynen/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-byter-certified-adviser-till-redeye-ab/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utforskar-strategiska-alternativ/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-utvardering-av-fullstandiga-resultat-fran-pointer-studien/ 2026-08-11T22:02:42+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-vid-kommande-investerarkonferenser/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-juni-2025/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-september-2025/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-topline-resultat-fran-fas-2b-studien-pointer/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-late-breaking-resultat-fran-fas-2b-studien-pointer-vid-asn-kidney-week-2025/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-nya-positiva-effektdata-fran-sekundara-analyser-av-fas-2a-studien-akita/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-att-datainsamlingen-till-fas-2b-studien-pointer-ar-slutford/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-ytterligare-akita-resultat-vid-ledande-amerikansk-njurmedicinsk-konferens/ 2026-08-11T22:02:43+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-att-patientrekryteringen-till-fas-2b-studien-pointer-har-slutforts/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-positivt-utfall-av-den-andra-planerade-sakerhetsanalysen-i-fas-2b-studien-pointer/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-uformningen-av-pointer-studien-vid-vetenskaplig-konferens/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-15-maj-2025/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2025/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-forandringar-i-antal-aktier-och-roster/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-2/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2024/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-utfallet-i-foretradesemissionen/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/emissionsaktuella-guard-therapeutics-bjuder-in-till-bolagspresentation/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/tva-tredjedelar-av-patienterna-rekryterade-till-guard-therapeutics-fas-2b-studie-pointer/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-informationsdokument-avseende-foretradesemission/ 2026-08-11T22:02:44+00:00 https://disruptivepharma.se/press-nyheter/styrelsen-for-guard-therapeutics-har-beslutat-om-tidigare-aviserad-foretradesemission-om-cirka-150-msek/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-6-mars-2025-och-offentliggorande-av-preliminar-tidsplan-for-foretradesemission/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-positivt-utfall-av-den-forsta-oberoende-sakerhetsanalysen-i-fas-2b-studien-pointer/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-for-2024/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-2/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-avser-att-besluta-om-en-foretradesemission-om-cirka-150-msek/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-etablerar-vetenskaplig-kommittee-for-att-starka-fas-3-utvecklingen-av-rmc-035/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/25-av-patienterna-rekryterade-till-guard-therapeutics-kliniska-fas-2b-studie-pointer/ 2026-08-11T22:02:45+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2025/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-september-2024/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/forsta-patienten-i-europa-doserad-i-den-kliniska-fas-2b-studien-pointer/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-utfall-i-foretradesemission/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-fas-2-resultat-publicerade-i-ledande-vetenskaplig-tidsskrift/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-prospekt-med-anledning-av-forestaende-foretradesemission/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/forsta-patienten-doserad-i-guard-therapeutics-fas-2b-studie-pointer/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-genomfor-aviserad-foretradesemission-kompensationsemission/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-juni-2024/ 2026-08-11T22:02:46+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-regulatoriska-eu-godkannanden-att-inkludera-patienter-till-fas-2b-studien-pointer/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-3-juli-2024-och-offentliggorande-av-preliminar-tidsplan-for-kompensationsemission/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-3/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-genomfor-en-riktad-nyemission-om-cirka-60-miljoner-kronor-och-avser-att-genomfora-en-kompensationsemission/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-forskning-publicerad-i-american-journal-of-physiology-renal-physiology/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-8-maj-2024/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2024/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2023/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-forsta-regulatoriska-godkannandet-av-fas-2b-studien-pointer/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-3/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-for-2023/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterade-utvecklingsstrategi-och-nya-prekliniska-resultat-pa-rd-update/ 2026-08-11T22:02:47+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-bjuder-in-till-rd-update-den-30-januari/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/fda-ger-guard-therapeutics-positiv-aterkoppling-gallande-fortsatt-utvecklingsplan-for-rmc-035/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/styrelsen-i-guard-therapeutics-international-ab-publ-faststaller-avstamningsdag-for-beslutad-sammanlaggning-av-aktier/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2024/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-27-november-2023/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-september-2023/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-4/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-late-breaking-clinical-trial-abstract-pa-asn-kidney-week-2023/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-ger-fordjupad-information-om-utvecklingsstrategin-for-rmc-035/ 2026-08-11T22:02:48+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-robust-effekt-av-rmc-035-i-fas-2-akita-och-avancerar-kliniska-utvecklingsprogrammet/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-juni-2023/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/sista-patientbesoket-genomfort-i-guard-therapeutics-kliniska-fas-2-studie-akita/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/studieresultat-med-guard-therapeutics-rmc-035-inom-njurtransplantation-bekraftar-tidigare-positiva-dataanalyser/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-9-maj-2023/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2023/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/justeringar-infor-arsstamma-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-ger-uppdaterad-information-kring-fas-2-studien-akita/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-stanger-sin-kliniska-fas-2-studie-akita-efter-rekommendation-fran-oberoende-expertkommitte/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2022/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-4/ 2026-08-11T22:02:49+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-positiva-kliniska-data-med-rmc-035-hos-patienter-som-genomgar-njurtransplantation/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-24-februari-2023/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-for-2022/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/resultat-fran-guard-therapeutics-fas-1b-studie-i-hjartkirurgi-publicerade-i-kidney-international-reports/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/forsta-patienten-i-usa-doserad-i-guard-therapeutics-fas-2-studie-akita/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/halften-av-patienterna-har-doserats-i-fas-2-studien-akita/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-5/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-patentgodkannande-for-rmc-035-i-kina/ 2026-08-11T22:02:50+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2023/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-13-december-2022/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-september-2022/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-6/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-har-beslutat-att-genomfora-en-riktad-nyemission-om-120-msek-delvis-villkorad-av-efterfoljande-godkannande-fran-extra-bolagsstamma/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-undersoker-forutsattningarna-att-genomfora-en-riktad-nyemission-om-cirka-115-msek/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-beviljas-fast-track-designation-fran-fda-for-rmc-035/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-ind-godkannande-fran-fda-for-rmc-035/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/presentationerna-fran-guard-therapeutics-kapitalmarknadsdag-finns-nu-tillgangliga-pa-bolagets-hemsida/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/forsta-njurtransplanterade-patienten-doserad-med-guard-therapeutics-lakemedelskandidat-rmc-035/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-juni-2022/ 2026-08-11T22:02:51+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-bjuder-in-till-kapitalmarknadsdag/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-far-godkannande-fran-lakemedelsverket-for-klinisk-studie-av-rmc-035-inom-njurtransplantation/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-12-maj-2022/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2022/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rekryterar-ny-head-of-cmc/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2021/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-lamnar-fordjupad-information-om-klinisk-fas-2-studie/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/forsta-patienten-har-doserats-i-guard-therapeutics-kliniska-fas-2-studie-av-rosgard/ 2026-08-11T22:02:52+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-5/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-januari-december-2021/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-godkannande-att-expandera-den-globala-kliniska-fas-2-studien-av-rosgard-till-kanada/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-ansokan-om-att-genomfora-en-klinisk-fas-2-studie-av-rosgard-har-godkants-av-den-tyska-lakemedelsmyndigheten/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-michael-reusch-till-chief-medical-officer/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2022/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-slutligt-utfall-i-foretradesemission/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-preliminart-utfall-i-foretradesemission/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-tillaggsprospekt/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-positiva-resultat-fran-prekliniska-studier/ 2026-08-11T22:02:53+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-prospekt-med-anledning-av-forestaende-foretradesemission-2/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-den-8-november-2021/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-september-2021/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-7/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-genomfor-under-forutsattning-av-godkannande-fran-extra-bolagsstamma-en-riktad-nyemission-om-cirka-54-miljoner-kronor-och-en-foretradesemission-om-hogst-cirka-128-miljoner-kronor/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-avser-att-genomfora-en-kapitalanskaffning-om-cirka-180-miljoner-kronor/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-positiva-resultat-fran-fas-1b-studie/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-patent-for-rosgard-godkant-av-det-europeiska-patentverket/ 2026-08-11T22:02:54+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-juni-2021/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/sista-patienten-rekryterad-till-guard-therapeutics-fas-1b-studie-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-har-etablerat-en-vetenskaplig-kommitte-med-framstaende-internationella-lakare-och-forskare-inom-thoraxkirurgi-intensivvard-och-njurmedicin/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-guard-therapeutics-international-ab-publ-den-12-maj-2021/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-januari-mars-2021/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-publicerar-arsredovisning-2020/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-6/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-forhandsbesked-om-patentgodkannande-for-rosgard-i-europa/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-valberedning-foreslar-inval-av-johan-bygge-och-pia-gideon-till-styrelsen-vid-den-ordinarie-bolagsstamman/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-patentgodkannande-for-rosgard-fran-det-amerikanska-patentverket/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/forsta-patienten-doserad-i-guard-therapeutics-fas-1b-studie-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-bokslutskommunike-januari-december-2020/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-sara-thuresson-till-head-of-clinical-operations/ 2026-08-11T22:02:55+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-patent-godkant-i-australien/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-godkannande-att-starta-fas-1b-studie-av-rosgard-i-tyskland/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-har-genomfort-ett-framgangsrikt-pre-ind-mote-med-det-amerikanska-lakemedelsverket-fda/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-ann-kristin-myde-till-head-of-global-project-management/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-notice-of-allowance-for-rosgard-fran-det-amerikanska-patentverket/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-valberedningen-for-2021/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-januari-september-2020/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-meddelar-sista-dag-for-handel-i-bta/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/foretradesemissionen-i-guard-therapeutics-tecknades-till-214-procent-och-overtilldelningsemission-utnyttjas-fullt-ut/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-tillaggsprospekt-2/ 2026-08-11T22:02:56+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-forlanger-teckningsperioden-i-den-pagaende-foretradesemissionen-till-den-1-oktober-2020/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-positiva-top-line-resultat-fran-fas-1-studie-av-rosgard-i-individer-med-nedsatt-njurfunktion/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-prospekt-med-anledning-av-forestaende-foretradesemission-3/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-2/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-guard-therapeutics-international-ab-publ-8/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-halvarsrapport-januari-juni-2020/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-genomfor-en-fullt-ut-sakerstalld-foretradesemission-om-cirka-668-msek-samt-foreslar-bemyndigande-for-en-overtilldelningsemission-om-ytterligare-cirka-98-msek/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-positiva-interimresultat-fran-en-fas-1-studie-av-rosgard-i-individer-med-nedsatt-njurfunktion/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-rapporterar-positiva-top-line-resultat-fran-den-avslutande-studien-i-det-kliniska-fas-1-programmet-av-rosgard-i-friska-forsokspersoner/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterar-positiv-uppfoljningsanalys-fran-fas-1-studie-av-rosgard/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-peter-gilmour-till-preklinisk-utvecklingschef/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utser-karin-botha-till-ny-chief-financial-officer/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-byter-certified-adviser/ 2026-08-11T22:02:57+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-den-14-maj-2020-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-delarsrapport-for-forsta-kvartalet-2020/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-offentliggor-arsredovisning-for-2019/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/rattelse-kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-guard-therapeutics-international-ab-publ-7/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-erhaller-myndighetsgodkannande-infor-nasta-steg-i-det-kliniska-fas-1a-programmet-for-rosgard/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-rapporterar-positiva-top-line-resultat-fran-en-klinisk-fas-1a-studie-av-rosgard/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-bokslutskommunike-2019/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-bokslutskommunike-2019-2/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-rekryterar-lars-olsson-som-head-of-cmc/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-inleder-screening-av-patienter-till-den-avslutande-delen-i-fas-1a-programmet-for-rosgard/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-erhaller-godkannande-fran-etikprovningsmyndigheten-infor-den-avslutande-delen-i-fas-1a-programmet-for-rosgard/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-inleder-klinisk-studie-for-att-dokumentera-rosgards-farmakokinetik-vid-nedsatt-njurfunktion/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-presenterar-valberedningen-for-2020/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-international-ab-guard-therapeutics-lamnar-kompletterande-information-avseende-nyttjandet-av-teckningsoptioner-av-serie-2019/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2019-01-01-till-2019-09-30/ 2026-08-11T22:02:58+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-presenterade-prekliniska-forskningsresultat-for-rosgard-pa-asn-kidney-week/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-utokar-dosintervallet-i-fas-1a-programmet-for-rosgard-baserat-pa-gynnsamma-sakerhetsdata/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/guard-therapeutics-teckningsoptioner-av-serie-2019-utnyttjades-till-88-procent/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-byter-namn-till-guard-therapeutics/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-den-23-oktober-2019-i-a1m-pharma-ab/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-sista-dag-for-nyttjande-av-teckningsoptioner-av-serie-2019-ar-den-25-oktober-2019/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/nyttjandeperioden-for-teckningsoptioner-av-serie-2019-inleds-7-oktober-2019-teckningsforbindelser-om-18-fran-vd-och-storre-innehavare/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rapporterar-positiva-top-line-resultat-fran-en-fas-1a-studie-av-rosgard/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2019-01-01-till-2019-06-30/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-forskningsresultat-for-rosgard-uppmarksammas-pa-varldens-storsta-kongress-inom-njurmedicin/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-erhaller-besked-om-kommande-godkannande-av-patent-i-usa/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-utser-ny-chief-financial-officer/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-genomfor-riktad-nyemission-om-cirka-272-mkr-for-att-finansiera-utokade-kliniska-studier-position/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-cfo-lamnar-sin-position/ 2026-08-11T22:02:59+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-29-maj-2019-i-a1m-pharma-ab/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-styrelseordforande-avbojer-omval/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2019-01-01-till-2019-03-31/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-forstarker-organisationen-infor-den-fortsatta-kliniska-utvecklingen-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-arsredovisning-for-2018/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/nya-styrelseledamoter-i-a1m-pharma-foreslas-till-inval-vid-ordinarie-bolagsstamma-den-29-maj-2019/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-a1m-pharma-ab/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/doseringen-inledd-i-a1m-pharmas-fas-1-studie-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-sista-dag-for-handel-med-btu/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-startar-den-forsta-kliniska-studien-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/bokslutskommunike-2018-01-01-till-2018-12-31-omsandning/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-foretradesemission-slutford-tillfors-705-msek/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-investerartraff-i-samband-med-foretradesemissionen/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-prospekt-och-ny-finansiell-information-som-aterfinns-i-prospektet/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-senarelagger-bokslutskommuniken-for-2018/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-investerartraffar-i-samband-med-foretradesemissionen/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab/ 2026-08-11T22:03:00+00:00 https://disruptivepharma.se/press-nyheter/foreslagen-ny-styrelseledamot-i-a1m-star-inte-langre-till-forfogande/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-utvecklingschef-lamnar-bolaget/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-publ/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-foreslar-100-procent-sakerstalld-foretradesemission-om-705-msek-varav-31-msek-toppgaranterat-av-langsiktiga-investerare/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-genomfor-byte-av-vd-och-reducerar-kostnadsmassan/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/anders-ermen-ny-styrelseordforande-i-a1m-pharma/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-receives-observation-status-on-nasdaq-first-north/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/swedish-medical-products-agency-grants-a1m-pharma-permission-to-start-a-clinical-phase-i-study-of-rosgard/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-lamnar-in-fornyad-ansokan-till-lakemedelsverket-om-klinisk-provning-med-rosgard/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2018-01-01-till-2018-06-30/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-prioriterar-indikationen-akut-njurskada-i-den-fortsatta-utvecklingen-av-rosgard-baserat-pa-positiva-prekliniska-data/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rekryterar-chief-medical-officer/ 2026-08-11T22:03:01+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-lakemedelskandidat-rosgard-skyddar-mot-akut-njurskada-i-amerikansk-preklinisk-studie/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rapporterar-positiva-resultat-fran-preklinisk-studie-inom-akuta-njurskador/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-byter-tillverkningspartner-av-lakemedelskandidaten-rosgard/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/fornyad-ansokan-till-lakemedelsverket-under-juli-klinisk-provning-med-rosgard-forskjuts-ett-kvartal/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-a1m-pharma/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2018-01-01-till-2018-03-31/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-arsredovisning-for-2017/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-a1m-pharma-ab-publ/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/helena-brouneus-foreslas-som-ny-styrelseledamot-i-a1m-pharma/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/sista-dag-for-handel-med-bta/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-kompletterar-ansokan-till-lakemedelsverket/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-utfall-i-foretradesemissionen/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/idag-inleds-teckningsperioden-i-a1m-pharmas-foretradesemission/ 2026-08-11T22:03:02+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-prospekt-inleder-teckningsperiod-7-mars/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rekryterar-fredrik-werner-som-cfo/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-presenterar-pa-aktiedagen-i-stockholm-den-5-mars/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab-2/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/bokslutskommunike-2017-01-01-till-2017-12-31/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/godkannande-av-patent-i-australien-for-behandling-av-mitokondrierelaterade-sjukdomar-omsandning/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/godkannande-av-patent-i-australien-for-behandling-av-mitokondrierelaterade-sjukdomar/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-foretradesemission-om-83-msek-for-genomforande-av-kliniska-studier/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-lamnar-in-ansokan-till-lakemedelsverket-om-att-fa-genomfora-klinisk-fas-i-studie-med-rosgard/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/produkt-for-stralbehandling-med-prrt-far-marknadsgodkannande-i-usa-vaxande-patientunderlag-for-a1m-pharma/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/nyhetsbrev-januari-2018-2018-ar-aret-vi-gar-in-i-klinisk-fas/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-inleder-sitt-kliniska-program-ingar-forskningssamarbete-for-att-undersoka-skadliga-effekter-vid-stralbehandlingen-prrt/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/christina-ostberg-lloyd-lamnar-a1m-pharmas-styrelse/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/utfall-av-nyttjande-av-teckningsoptioner-av-serie-2017-i-a1m-pharma/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-styrelse-och-ledning-nyttjar-teckningsoptioner/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-bjuder-in-till-livesand-presstraff/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/idag-inleds-teckningsperioden-i-a1m-to-av-serie-2017/ 2026-08-11T22:03:03+00:00 https://disruptivepharma.se/press-nyheter/nordeas-analys-av-a1m-pharma-publicerad/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2017-01-01-till-2017-09-30/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/positivt-resultat-fran-glp-toxicitetsstudier-fardigstaller-nu-ansokan-om-start-av-kliniska-studier/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/professor-bo-akerstrom-erhaller-anslag-fran-vetenskapsradet-om-12-msek/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rosgard-skyddar-benmarg-vid-stralbehandling-patentansokan-inlamnad/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-forst-i-varlden-att-producera-a1m-i-stor-skala-under-full-gmp-infor-kliniska-studier/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-anlitar-svensk-cro-partner-for-kliniska-studier/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rekryterar-marie-wallen-ohman-som-projektledare-for-bolagets-kliniska-utveckling/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/nyhetsbrev-oktober-2017-handelserik-host-vantar/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-medverkar-vid-rodman-renshaw-global-investment-conference-i-new-york/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/nyhetsbrev-augusti-2017-i-slutfasen-av-det-prekliniska-arbetet/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/halvarsrapport-2017-01-01-till-2017-06-30/ 2026-08-11T22:03:04+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-medverkar-i-tv-program-om-medicinska-innovationer-pa-fox-business-i-usa/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/nyhetsbrev-juni-2017-allt-narmare-kliniska-studier/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-listning-av-teckningsoptioner-fran-och-med-20-juni-2017-pa-nasdaq-first-north/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-erhaller-villkorat-godkannande-fran-nasdaq-first-north-handelsstart-20-juni-2017/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-meddelar-framsteg-inom-den-prekliniska-utvecklingen-av-rosgard/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-erhallit-besked-om-kommande-godkannande-av-patent-i-kanada-for-diagnostik-och-behandling-av-havandeskapsforgiftning/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-delarsrapport-2017-01-01-till-2017-03-31/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamman-i-a1m-pharma-ab-publ/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/avstamningsdag-for-sammanlaggning-av-aktier-samt-omrakning-av-teckningsoptioner/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-vd-tomas-eriksson-har-kopt-84-444-units-i-bolaget-motsvarande-253-332-aktier/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-omvandling-av-btu-till-aktier-och-teckningsoptioner/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/arsredovisning-2016/ 2026-08-11T22:03:05+00:00 https://disruptivepharma.se/press-nyheter/utfall-av-a1m-pharmas-foretradesemission/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-a1m-pharma-ab-publ-2/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/offentliggorande-av-tillaggsprospekt-avseende-a1m-pharmas-foretradesemission/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-senarelagger-datum-for-arsstamma-till-den-16-maj-2017/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-rosgard-uppvisar-stark-skyddseffekt-mot-njurskador-vid-stralbehandling-i-preklinisk-langtidsstudie/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/idag-inleds-teckningstiden-i-a1m-pharmas-foretradesemission/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-offentliggor-prospekt-inleder-teckningsperiod-24-mars/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/bokslutskommunike-2016-01-01-till-2016-12-31/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-publ-2/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-flyttar-fram-den-extra-bolagsstamman-till-den-14-mars-2017/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-framgangsrikt-genomfort-storskalig-tillverkning-av-den-aktiva-substansen-i-rosgard-inleder-toxicitetsstudier-enligt-glp/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-2/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-beslutar-om-foretradesemission-om-1229-msek-sammanlaggning-av-aktier-samt-ansoker-om-listning-pa-nasdaq-first-north/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-fardigstaller-immunogenicitetsstudie-med-rosgard/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-mitokondrieskyddande-effekt-hos-ra1m-i-prekliniska-studier/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/rosgard-visar-upp-njurskyddande-effekt-vid-stralbehandling/ 2026-08-11T22:03:06+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-genomfort-framgangsrika-prekliniska-toxicitets-sakerhetsstudier-inom-havandeskapsforgiftning/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-fardigstaller-industriell-tillverkningsprocess-och-tar-hem-cellbanker-till-lund/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2016-01-01-till-2016-09-30/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-valjer-njurskydd-vid-cancerbehandling-som-forsta-indikation-inom-akut-njurskada/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/halvarsrapport-2016-01-01-till-2016-06-30/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-erhallit-besked-om-kommande-godkannande-av-patent-i-europa-for-behandling-av-mitokondrierelaterade-sjukdomar/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/verifierar-stabilitet-och-kompatibilitet-hos-bolagets-lakemedelskandidat-rmc-035-infor-kommande-toxicitetsstudier/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-anlitar-erfaren-europeisk-cro-partner-for-prekliniska-toxikologistudier/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/foretradesemission-fulltecknad/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/idag-inleds-teckningstiden-i-a1m-pharmas-nyemission/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/offentliggorande-av-prospekt-och-information-om-investerartraffar/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-inleder-forskningssamarbete-med-varldsledande-csl-behring-inom-kombinerade-behandlingar-med-a1m-och-plasmaproteiner/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab-3/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma-i-a1m-pharma-ab-publ/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/baulos-capital-belgium-sa-undantaget-fran-budplikt/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2016-01-01-till-2016-03-31/ 2026-08-11T22:03:07+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-3/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/beslut-om-foretradesemission-villkorat-av-godkannande-vid-extra-bolagsstamma/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-erhallit-besked-om-kommande-godkannande-av-patent-i-japan/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/arsredovisning-2015/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-arsstamma-i-a1m-pharma-ab-publ-3/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-fardigstaller-lakemedelskandidat-for-behandling-av-havandeskapsforgiftning-och-ansoker-om-substanspatent/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/bokslutskommunike-2015-01-01-till-2015-12-31/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-utokar-och-forlanger-avtal-med-europeisk-kontraktstillverkare/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/erhaller-godkannande-av-nytt-patent/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/framgangsrikt-mote-for-a1m-pharma-med-lakemedelsverket-for-vetenskaplig-radgivning-kring-initialt-utvecklingsprogram/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-nyckelpersoner-forvarvar-optioner-av-serie-2015-2018/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-avslutar-tjanst-om-likviditetsgaranti/ 2026-08-11T22:03:08+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-teckningsoptioner-av-serie-to-1-nyttjades-till-886/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/insynspersoner-och-samarbetspartners-avser-nyttja-teckningsoptioner-av-serie-to-1/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/paminnelse-om-nyttjande-av-teckningsoptioner-av-serie-to-1/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab-publ/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/har-erhallit-besked-om-kommande-godkannande-av-patent-i-ryssland/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/huvudagare-nyttjar-200-000-teckningsoptioner-av-serie-to-1/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/forskningsron-okar-kunskapen-om-a1ms-formaga-att-oskadliggora-giftigt-fritt-hemoglobin/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-har-erhallit-besked-om-kommande-godkannande-av-patent-i-europa/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/idag-inleds-nyttjandeperioden-for-teckningsoptioner-av-serie-to-1/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-publ-3/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-extra-bolagsstamma-i-a1m-pharma-ab-publ-2/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/avsikt-att-kalla-till-ny-extra-bolagsstamma-for-justering-av-villkor-i-incitamentsprogram-2015-2018/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-inleder-forskningssamarbete-med-fred-hutchinson-cancer-research-centre-kring-proteinet-a1ms-verkningsmekanismer/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2015-01-01-till-2015-09-30/ 2026-08-11T22:03:09+00:00 https://disruptivepharma.se/press-nyheter/nytt-datum-for-publicering-av-delarsrapport-tre-2015/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/tva-avhandlingar-starker-det-vetenskapliga-stodet-for-behandling-med-a1m-vid-oxidativ-stress/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/kallelse-till-extra-bolagsstamma-i-a1m-pharma-ab-publ-4/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/nya-forskningsron-fordjupar-kunskapen-om-fritt-hemoglobin-och-a1m/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/martin-austin-utsedd-till-business-development-director-i-a1m-pharma/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-utokar-med-labblokaler-for-egen-tillverkning-av-a1m/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/publicerar-positiva-studieresultat-med-betydelse-for-diagnostik-och-behandling-av-havandeskapsforgiftning/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/halvarsrapport-2015-01-01-till-2015-06-30/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharma-blir-partner-till-varldsledande-intresseorganisation-i-usa/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/forstarker-bolaget-med-utvecklingschef-och-director-medical-affairs/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/starkt-forsta-halvar-for-a1m-pharma/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/inleder-samarbete-med-ledande-europeisk-kontraktstillverkare-av-lakemedel/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/delarsrapport-2015-01-01-till-2015-03-31/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/inleder-prekliniska-njurstudier-i-samarbete-med-tysk-forskningsorganisation/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/sista-dag-for-handel-med-btu/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/kommunike-fran-arsstamma/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/proof-of-concept-for-behandling-av-havandeskapsforgiftning-med-a1m-publicerat-i-vetenskaplig-artikel/ 2026-08-11T22:03:10+00:00 https://disruptivepharma.se/press-nyheter/a1m-pharmas-emission-kraftigt-overtecknad/ 2026-08-11T22:03:11+00:00 https://disruptivepharma.se/press-nyheter/har-erhallit-besked-om-godkannande-av-patent-i-ryssland/ 2026-08-11T22:03:11+00:00 https://disruptivepharma.se/press-nyheter/disruptive-pharma-ringer-i-oppningsklockan-pa-nasdaq-stockholm/ 2026-08-18T15:20:00+00:00 https://disruptivepharma.se/press-nyheter/disruptive-pharma-offentliggor-delarsrapport-for-januari-juni-2026/ 2026-08-20T06:30:00+00:00